Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 9/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.43 |
| ▸ | GSK3B | P49841 | 7/20 | 0.43 |
| ▸ | PRKG1 | Q13976 | 7/20 | 0.43 |
| ▸ | JAK2 | O60674 | 7/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.43 |
| ▸ | PRKACA | P17612 | 7/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 7/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 6/20 | 0.43 |
| ▸ | HIPK4 | Q8NE63 | 6/20 | 0.43 |
| ▸ | AKT1 | P31749 | 5/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.43 |
| ▸ | SGK2 | Q9HBY8 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170615 | 0.85 | JAK2 (0.51) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1229617 | 0.84 | GSK3B (0.45) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1228234 | 0.82 | JAK2 (0.52) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1229259 | 0.78 | ROCK1 (0.54) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1229917 | 0.78 | TTK (0.46) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1229781 | 0.78 | RPS6KB1 (0.62) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1228419 | 0.75 | ROCK1 (0.45) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1228816 | 0.71 | ROCK2 (0.46) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1228940 | 0.69 | RPS6KB1 (0.44) | ROCK1CLK4GSK3BPRKG1JAK2 | |
| SCHEMBL1228428 | 0.68 | CDK7 (0.52) | ROCK1CLK4GSK3BPRKG1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | claimed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | claimed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | SGK1, SGK3, SGK2 | ROCK1 523/4885CLK4 156/4885GSK3B 108/4885 |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | CHEK2, CHEK1, SIK2 | ROCK1 979/4885CLK4 66/4885GSK3B 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.